Mequon Doctor Sentenced to 27 Months for Selling Prescriptions for Cash

A former emergency room physician in Mequon, Wisconsin, was sentenced October 2 to two years and three months in federal prison for running what prosecutors described as a cash-for-prescriptions operation that dispensed tens of thousands of pills — including the addiction medication buprenorphine — to customers without a legitimate medical purpose.

Jerry Jones III pleaded guilty on June 29 to one count of conspiracy to distribute controlled substances outside a professional practice and without medical purpose. Federal prosecutors said the conduct ran from January 2021 through September 2025 and generated $294,850.72 in payments through CashApp and Venmo.

"We trust our medical professionals to use their license and the authority granted to them to do only what is safe and in the best interests of their patient," said First Assistant U.S. Attorney Brad Schimel in a statement released by the U.S. Attorney's Office for the Eastern District of Wisconsin. "This defendant abused that trust and contributed significantly to the deadly drug epidemic afflicting our communities by selling dangerous drugs for cash. Like any other illegal drug trafficker, he belongs in prison for such conduct."

What prosecutors say was sold

As a licensed provider, Jones held a Drug Enforcement Administration registration authorizing him to prescribe controlled substances for legitimate medical reasons. According to the U.S. Attorney's Office, he instead conspired to distribute amphetamine-dextroamphetamine, methylphenidate, buprenorphine and other controlled drugs outside the usual course of professional practice, and charged patients more for higher doses.

The government's accounting of the prescriptions covers 12,885 pills of Adderall, 8,121 pills of Ritalin, 143,282 units of Schedule III controlled substances, 35,944 units of Schedule IV drugs and 12,374 units of Schedule V drugs. Buprenorphine, the active ingredient in Suboxone and a first-line treatment for opioid use disorder, falls in Schedule III.

The unusual twist in the case

What sets the prosecution apart from the more common opioid pill-mill cases is the presence of buprenorphine in the mix. Buprenorphine is normally the medication that prosecutors and public health officials want in more hands, not fewer: it is one of three drugs approved for medication-assisted treatment, and the federal government has spent years loosening rules so that more clinicians can prescribe it.

The concern in diversion cases is different from the concern with oxycodone or hydrocodone. Buprenorphine has a ceiling effect that limits respiratory depression, which is part of why it is considered safer than full opioid agonists. But unmonitored supply still creates problems: patients who buy it without a diagnosis skip the counseling, toxicology screening and dose adjustment that make the medication effective, and pills can move into a secondary market where people use them to self-manage withdrawal or to bridge gaps in legitimate supply.

The stimulants in the case — Adderall and Ritalin — carry their own risks and are among the most diverted prescription drugs in the country.

How the case was built

Prosecutors built the case around the payment trail as much as the prescriptions themselves. The government says Jones received nearly $295,000 through CashApp and Venmo from customers over roughly four and a half years, and that he raised his prices for higher doses — a charging structure that the U.S. Attorney's Office cited as evidence the practice was a commercial operation rather than a medical one.

The sentencing judge in the Eastern District of Wisconsin imposed a 27-month term. Schimel, who served as Wisconsin's attorney general from 2015 to 2019, framed the case as straightforward consumer protection dressed as medicine.

Why prescribing cases keep coming

Federal prosecutors have brought a steady stream of cases against clinicians in the fentanyl era, and the pattern has shifted with the drug supply. Cases built on oxycodone mill operations dominated the 2000s and 2010s; more recent prosecutions have increasingly involved stimulants, sedatives and addiction medications sold alongside them. Those cases put regulators in an awkward position, because the volume of legitimate buprenorphine prescribing is still far below what the opioid crisis requires, and overly aggressive enforcement can deter clinicians from treating patients at all.

The federal government's own data has pointed in both directions: diversion prosecutions continue while health agencies push to expand treatment capacity. In Wisconsin, the state's jails and prisons have doubled access to opioid treatment medications over the past four years rather than restricting it, part of a national shift toward continuing medication behind bars and at release.

Jones is scheduled to begin serving his sentence in federal custody; the sentencing announcement did not describe supervised release conditions. People seeking treatment for opioid use disorder, or concerned about their own prescriptions, can find detoxification and treatment options through licensed providers.